Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prostate CARE Study
2006-004564-32Phase 2Terminated
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and Rhenium-188-HEDP in castration-resistant prostate cancer (CRPC) and prostate cancer (PCa), sponsored by University Medical Center Utrecht. Primary endpoint: Dose-limiting toxicity and maximum tolerated dose. Started Nov 2006; status: terminated.
02
Drugs
capecitabineRhenium-188-HEDP
03
Conditions
castration-resistant prostate cancer (CRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-004564-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004564-32.